Stocktoria
Minerva Neurosciences, Inc. NERV
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2014-06-25
Minerva Neurosciences, Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | — | $0 | $0 | $0 | $0 |
| R&D expense | $5.8M | $11.9M | $12.7M | $14.6M | $32.0M |
| Operating income | -$15.1M | -$21.8M | -$23.1M | -$25.2M | -$45.4M |
| Income tax | — | — | — | — | -$1.8M |
| Net income | -$293.4M | $1.4M | -$30.0M | -$32.1M | -$49.9M |
| EPS (diluted) | $-34.67 | $0.19 | $-4.61 | $-6.01 | $-9.35 |
| Operating cash flow | -$13.5M | -$19.6M | -$14.8M | -$24.6M | -$24.6M |
| Free cash flow | — | — | — | -$24.7M | — |
| Cash & equivalents | $82.3M | $21.4M | $40.9M | $36.1M | $60.8M |
| Total assets | $98.0M | $37.1M | $56.9M | $55.1M | $77.1M |
| Total liabilities | $233.8M | $62.8M | $85.4M | $75.1M | $69.1M |
| Shareholders' equity | -$140.7M | -$25.7M | -$28.5M | -$20.0M | $8.0M |
Source: SEC EDGAR filings · CIK 0001598646 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.